GTHX | Biotech Message Board Posts

  • Get 3 months of ad-free premium service for every $25 you contribute
    to support critical site improvement efforts.
    With no recurring subscription
    to worry about, this an ideal way to test drive our premium service.

    Premium features, such as multi-message viewing (i.e., being able to open
    up to 100 messages with a single click) can save you lots of time
    over the course of a busy day, to say nothing of an entire year!
    Watch this 2-min video to see why premium is right for you.

    *Offer expires at midnight

Biotech   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27591 of 28416  at  6/18/2019 9:11:49 PM  by



What the drug does:  Trilaciclib is a first-in-class myelopreservation agent designed to protect the bone marrow from damage by chemotherapy and improve patient outcomes.
It is in Phase 2 clinical trials for women with TNBC type breast cancer: 

Breast cancer isn’t a single disease. It’s made up of several subtypes. One of these subtypes is known as triple-negative breast cancer (TNBC). TNBC doesn’t grow in response to the hormones estrogen, progesterone, or HER2/neu.

Therefore, TNBC doesn’t respond to hormonal therapies that target the receptors of these hormones. For this type of breast cancer, targeted treatments aren’t available like other subtypes of breast cancer.

According to John’s Hopkins Breast Center, about 10 to 20 percent of those who receive a breast cancer diagnosis have the triple-negative subtype. TNBC grows rapidly. It also has a higher grade and tends to metastasize (spread).

Because the cancer grows quickly, it’s often discovered between mammograms. However, the fast growth rate means that standard chemotherapies have a good chance of inducing remission.

TNBC has a much better response to conventional chemotherapy than other breast cancer subtypes.

Today's PR   G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone. Detailed data from this trial will be presented at a medical meeting later this year.
My understanding, TNBC currently can only be treated by chemo, which cannot differentiate what cells it kills.   G1's Trilaciclib is the first drug that improves a woman's survival rate during the treatment phase.   
About 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over the course of her lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 62,930 new cases of non-invasive (in situ) breast cancer.Feb 13, 2019
Thinking out loud, it may possibly prove to be beneficial to anyone who has to undergo chemotherapy... 

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 203
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
27597 Re: GTHX greymattermatters 1 6/19/2019 2:14:38 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by